{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:58:04Z","timestamp":1792627084982,"version":"4.5.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001946","name":"American Skin Association","doi-asserted-by":"publisher","award":["GSE298871"],"award-info":[{"award-number":["GSE298871"]}],"id":[{"id":"10.13039\/100001946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaci.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:22:26Z","timestamp":1749669746000},"page":"993-1007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skin"],"prefix":"10.1016","volume":"156","author":[{"given":"Patrick M.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Kurowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini P.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Gay-Mimbrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"G\u00f3mez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Alkon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Beaziz-Tordjman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Renert-Yuval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ruano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.06.002_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/15384101.2019.1707455","article-title":"Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo","volume":"19","author":"Campione","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaci.2025.06.002_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1755-148X.2010.00688.x","article-title":"Reduced skin homing by functional Treg in vitiligo","volume":"23","author":"Klarquist","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo","volume":"66","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","article-title":"Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients","volume":"35","author":"Elbuluk","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaci.2025.06.002_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: an update on pathophysiology and treatment options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s13671-014-0098-6","article-title":"The epidemiology of vitiligo","volume":"4","author":"Silverberg","year":"2015","journal-title":"Current Dermatology Reports"},{"key":"10.1016\/j.jaci.2025.06.002_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/ijd.IJD_142_18","article-title":"Vitiligo and psychiatric morbidity: a profile from a vitiligo clinic of a rural-based tertiary care center of eastern India","volume":"63","author":"Sarkar","year":"2018","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bjd.16049","article-title":"The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis","volume":"178","author":"Osinubi","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jamadermatol.2013.927","article-title":"Association between vitiligo extent and distribution and quality-of-life impairment","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2025.06.002_bib12","article-title":"The role of the Th1 chemokine CXCL10 in vitiligo","volume":"3","author":"Antonelli","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jaci.2025.06.002_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12955-016-0490-y","article-title":"Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL)","volume":"14","author":"Hedayat","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaci.2025.06.002_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2009.03.022","article-title":"The burden of vitiligo: patient characteristics associated with quality of life","volume":"61","author":"Homan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-1-58","article-title":"Quality of life in patients with vitiligo","volume":"1","author":"Parsad","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaci.2025.06.002_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/0019-5154.152508","article-title":"Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-east India","volume":"60","author":"Sangma","year":"2015","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13215","article-title":"Therapeutic options in vitiligo with special emphasis on immunomodulators: a comprehensive update with review of literature","volume":"33","author":"Agarwal","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.06.002_bib18","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14740338.2020.1729737","article-title":"Safety of the current drug treatments for vitiligo","volume":"19","author":"Lotti","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.jaci.2025.06.002_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: a review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2025.06.002_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaci.2025.06.002_bib22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jaad.2010.10.043","article-title":"Vitiligo: a comprehensive overview, part II: treatment options and approach to treatment","volume":"65","author":"Felsten","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib23","series-title":"Treasure Island (Fla)","article-title":"Vitiligo","author":"Ahmed Jan","year":"2021"},{"key":"10.1016\/j.jaci.2025.06.002_bib24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/1346-8138.15858","article-title":"Efficacy and safety of IV methylprednisolone pulse therapy for vitiligo: a retrospective study of 58 therapy experiences for 33 vitiligo patients","volume":"48","author":"Wada-Irimada","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10244","key":"10.1016\/j.jaci.2025.06.002_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2025.06.002_bib27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib28","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.06.002_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00403-016-1690-3","article-title":"Enhanced Th1 and Th17 responses in peripheral blood in active non-segmental vitiligo","volume":"308","author":"Zhen","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: an update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2025.06.002_bib31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib32","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.06.002_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2016.02.654","article-title":"614 Deregulation of chemotactic signals in segmental and non-segmental vitiligo","volume":"136","author":"El-Domyati","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","article-title":"The role of helper and regulatory T cells in the pathogenesis of vitiligo","volume":"60","author":"Basak","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2133.2012.11000.x","article-title":"Interleukin-4 genetic variants correlate with its transcript and protein levels in patients with vitiligo","volume":"167","author":"Imran","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: a pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venerol"},{"key":"10.1016\/j.jaci.2025.06.002_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2025.06.002_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK expression in vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2025.06.002_bib40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2025.06.002_bib41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15102","article-title":"Onset of vitiligo in a psoriasis patient on ixekizumab","volume":"34","author":"Marasca","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2025.06.002_bib43","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40261-020-00964-w","article-title":"New-onset vitiligo during treatment with secukinumab: report of two cases and review of the literature","volume":"40","author":"Nieto-Benito","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaci.2025.06.002_bib44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4 suppl","key":"10.1016\/j.jaci.2025.06.002_bib45","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ced.12464","article-title":"Interleukin-33 affects cytokine production by keratinocytes in vitiligo","volume":"40","author":"Li","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib49","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.jaad.2011.07.010","article-title":"Childhood- and later-onset vitiligo have diverse epidemiologic and clinical characteristics","volume":"66","author":"Nicolaidou","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051040","article-title":"Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2025.06.002_bib52","doi-asserted-by":"crossref","first-page":"9860","DOI":"10.1038\/s41598-017-10253-w","article-title":"Mapping architectural and transcriptional alterations in non-lesional and lesional epidermis in vitiligo","volume":"7","author":"Singh","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2025.06.002_bib53","article-title":"Vitiligo skin biomarkers associated with favorable therapeutic response","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib54","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through Jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib55","first-page":"316","article-title":"Comparison of skin transcriptome between responder and non-responder vitiligo lesions to cell transplantation: a clinical trial study","volume":"24","author":"Abdolahzadeh","year":"2022","journal-title":"Cell J"},{"key":"10.1016\/j.jaci.2025.06.002_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib57","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib58","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.jid.2019.04.008","article-title":"Major differences in expression of inflammatory pathways in skin from different body sites of healthy individuals","volume":"139","author":"Del Duca","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2019.01.015","article-title":"Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis","volume":"144","author":"Zhou","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.anai.2018.11.025","article-title":"Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib62","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical Bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1016\/j.jaci.2025.06.002_bib63","doi-asserted-by":"crossref","first-page":"979","DOI":"10.12688\/f1000research.73600.1","article-title":"Doublet identification in single-cell sequencing data using scDblFinder","volume":"10","author":"Germain","year":"2021","journal-title":"F1000Res"},{"issue":"7891","key":"10.1016\/j.jaci.2025.06.002_bib64","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","article-title":"Anatomically distinct fibroblast subsets determine skin autoimmune patterns","volume":"601","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.06.002_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154585","article-title":"Multimodal analyses of vitiligo skin identify tissue characteristics of stable disease","volume":"7","author":"Shiu","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2025.06.002_bib66","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2024.09.004","article-title":"Single-cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis disease group","volume":"155","author":"Alkon","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00403-022-02343-1","article-title":"Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI","volume":"315","author":"Kim","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaci.2023.09.021","article-title":"Improvements in immune\/melanocyte biomarkers with JAK3\/TEC family kinase inhibitor ritlecitinib in vitiligo","volume":"153","author":"Guttman-Yassky","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib69","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/emboj.2011.448","article-title":"CPEB2-eEF2 interaction impedes HIF-1\u03b1 RNA translation","volume":"31","author":"Chen","year":"2012","journal-title":"EMBO J"},{"key":"10.1016\/j.jaci.2025.06.002_bib70","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1600-0854.2009.00935.x","article-title":"The calcium channel mucolipin-3 is a novel regulator of trafficking along the endosomal pathway","volume":"10","author":"Martina","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.jaci.2025.06.002_bib71","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1038\/s41467-020-17212-6","article-title":"Rab27a co-ordinates actin-dependent transport by controlling organelle-associated motors and track assembly proteins","volume":"11","author":"Alzahofi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2025.06.002_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006636","article-title":"TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF","volume":"13","author":"Seberg","year":"2017","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jaci.2025.06.002_bib73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib74","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib75","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jid.2022.03.022","article-title":"Transcriptomic analysis of the major orphan ichthyosis subtypes reveals shared immune and barrier signatures","volume":"142","author":"Kim","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib76","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaci.2018.03.021","article-title":"Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature","volume":"143","author":"Malik","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib78","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/DAD.0000000000000171","article-title":"Changes of epidermal thickness in vitiligo","volume":"37","author":"Jung","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaci.2025.06.002_bib79","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000288166","article-title":"Epidermal permeability barrier recovery is delayed in vitiligo-involved sites","volume":"23","author":"Liu","year":"2010","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaci.2025.06.002_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn9299","article-title":"Altered epidermal proliferation, differentiation, and lipid composition: novel key elements in the vitiligo puzzle","volume":"8","author":"Kovacs","year":"2022","journal-title":"Sci Adv"},{"issue":"1 suppl 1","key":"10.1016\/j.jaci.2025.06.002_bib81","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1097\/DER.0000000000000764","article-title":"Transcriptomic profiling of tape-strips from moderate to severe atopic dermatitis patients treated with dupilumab","volume":"32","author":"Mikhaylov","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaci.2025.06.002_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12920-015-0133-x","article-title":"Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways","volume":"8","author":"Ewald","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jaci.2025.06.002_bib83","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1128\/MCB.01648-06","article-title":"Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues","volume":"27","author":"Meuter","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaci.2025.06.002_bib84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/iid3.87","article-title":"Interleukin-25 initiates Th2 differentiation of human CD4+ T cells and influences expression of its own receptor","volume":"3","author":"Bredo","year":"2015","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaci.2025.06.002_bib85","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/intimm\/dxr029","article-title":"An updated view on transcription factor GATA3-mediated regulation of Th1 and Th2 cell differentiation","volume":"23","author":"Yagi","year":"2011","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1359-6101(00)00015-0","article-title":"Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu","volume":"12","author":"Nakanishi","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2025.06.002_bib87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jphotobiol.2016.08.024","article-title":"Cross-talk between interferon-gamma and interleukin-18 in melanogenesis","volume":"163","author":"Zhou","year":"2016","journal-title":"J Photochem Photobiol B"},{"key":"10.1016\/j.jaci.2025.06.002_bib88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/pcmr.12190","article-title":"IFN-\u03b3 inhibits basal and \u03b1-MSH-induced melanogenesis","volume":"27","author":"Son","year":"2014","journal-title":"Pigment Cell and Melanoma Research"},{"key":"10.1016\/j.jaci.2025.06.002_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112811","article-title":"A meta-analysis of chemokines in vitiligo: recruiting immune cells towards melanocytes","volume":"14","author":"Speeckaert","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib90","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00403-019-01996-9","article-title":"Predominant role of innate pro-inflammatory cytokines in vitiligo disease","volume":"312","author":"Gholijani","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib91","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2230.2005.01987.x","article-title":"Vitiligo with inflammatory raised borders, associated with atopic dermatitis","volume":"31","author":"Sugita","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib92","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/imcb.12644","article-title":"CCL17\/TARC in autoimmunity and inflammation\u2014not just a T-cell chemokine","volume":"101","author":"Lupancu","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaci.2025.06.002_bib93","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/iid3.423","article-title":"CCL17-CCR4 axis contributes to the onset of vitiligo in mice","volume":"9","author":"Li","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaci.2025.06.002_bib94","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2022.11.023","article-title":"Skin TARC\/CCL17 increase precedes the development of childhood atopic dermatitis","volume":"151","author":"Halling","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib95","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib96","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/jid.2012.331","article-title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2-STAT6 signaling pathway","volume":"133","author":"Choi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib97","article-title":"Exploring the causal relationship between inflammatory cytokines and immunoinflammatory dermatoses: a Mendelian randomization study","volume":"11","author":"Li","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2025.06.002_bib98","article-title":"A Mendelian randomization study on the causal effects of circulating cytokines on the risk of vitiligo","volume":"11","author":"Liu","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2025.06.002_bib99","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdcr.2023.09.006","article-title":"Incidental improvement of programmed cell death-1 receptor inhibitor\u2013induced vitiligo after initiation of dupilumab therapy for refractory pruritus","volume":"42","author":"Robinson","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2025.06.002_bib100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2025.06.002_bib101","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.545","article-title":"Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report","volume":"101","author":"Takeoka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2025.06.002_bib102","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1346-8138.1998.tb02391.x","article-title":"Suplatast tosilate (IPD\u00ae), a new immunoregulator, is effective in vitiligo treatment","volume":"25","author":"Nihei","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib103","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00403-024-03182-y","article-title":"Ritlecitinib, a JAK3\/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo","volume":"316","author":"Yamaguchi","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaci.2025.06.002_bib104","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti\u2013tumor necrosis factor therapy: a 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdin.2020.10.007","article-title":"A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy","volume":"2","author":"Sachdeva","year":"2020","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaci.2025.06.002_bib106","article-title":"Tumor necrosis factor inhibitor\u2013induced eczematous eruption: a report of two cases and review of the literature","volume":"13","author":"Pagan-Leon","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jaci.2025.06.002_bib107","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/1346-8138.16634","article-title":"GATA3 ameliorates melanocyte injuries in vitiligo through SIRT3-mediated HMGB1 deacetylation","volume":"50","author":"Nie","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molimm.2018.02.014","article-title":"HMGB1 regulates T helper 2 and T helper 17 cell differentiation both directly and indirectly in asthmatic mice","volume":"97","author":"Li","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaci.2025.06.002_bib109","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaad.2017.11.034","article-title":"Lack of correlation of the patient-derived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index","volume":"78","author":"Coias","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib110","first-page":"171","article-title":"Imbalance of peripheral blood T helper type 17 responses in patients with vitiligo","volume":"17","author":"Behfarjam","year":"2018","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"7162","key":"10.1016\/j.jaci.2025.06.002_bib111","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2025.06.002_bib112","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/exd.14200","article-title":"Increased level of cathelicidin (LL-37) in vitiligo: possible pathway independent from vitamin D receptor gene polymorphism","volume":"29","author":"Atazadeh","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib113","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljaf041","article-title":"Comprehensive single-cell chromatin and transcriptomic profiling of peripheral immune cells in non-segmental vitiligo","author":"Gay-Mimbrera","year":"2025","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2025.06.002_bib115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/emmm.201200219","article-title":"Nrf2 links epidermal barrier function with antioxidant defense","volume":"4","author":"Sch\u00e4fer","year":"2012","journal-title":"EMBOL Mol Med"},{"key":"10.1016\/j.jaci.2025.06.002_bib116","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/ars.2011.3893","article-title":"Claudins: control of barrier function and regulation in response to oxidant stress","volume":"15","author":"Overgaard","year":"2011","journal-title":"Antioxid Redox Signal"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925006268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674925006268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:56:18Z","timestamp":1778903778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674925006268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0091674925006268"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.06.002","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic profiling of vitiligo patients shows polar immune dysregulation in involved and uninvolved skin","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}